Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer

abstract:
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

 Highlights

• •The PFS and response rate benefit from bevacizumab were similar regardless of age.
• •Grade ≥ 3 hypertension was more common with bevacizumab in older vs younger patients.
• •Thromboembolic events were not increased with bevacizumab in patients ≥65 vs <65 years.
• •In older patients, no PRO benefit was seen with bevacizumab versus chemotherapy alone.